

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: Translating Molecules into Treatments (C1)

February 25-March 1, 2018 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Paul W. H. I. Parren and Erica Ollmann Saphire

Sponsored by Bioverativ Therapeutics

Abstract & Scholarship Deadline: October 24, 2017 / Abstract Deadline: November 21, 2017 / Discounted Registration Deadline: December 19, 2017

SUNDAY, FEBRUARY 25

Arrival and Registration

MONDAY, FEBRUARY 26

Welcome and Keynote Address

Dennis R. Burton, The Scripps Research Institute, USA
Molecular Vaccine Design Guided by Human Anti-Viral Antibodies

Protective Antibody Responses

George Georgiou, University of Texas at Austin, USA
Dissecting Serum Antibodies at the Molecular Level

Erica Ollmann Saphire, The Scripps Research Institute, USA
Antibody-Mediated Protection Against Emerging Viral Threats

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Protection by Non-Conventional Antibodies

Short Talk(s) Chosen from Abstracts

Workshop 1: Vaccines

Short Talks Chosen from Abstracts

From Molecules to Vaccines

Nancy L. Haigwood, Oregon Health & Science University, USA
Antibodies as Change Agents to Control HIV/SIV

James E. Crowe, Jr., Vanderbilt University Medical Center, USA
Genetic and Structural basis for Virus Neutralization by Human Antibodies

Robert F. Garry, Tulane University Health Sciences Center, USA
Antibody Treatment of Lassa Virus: From the Field to the Lab and Back

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, FEBRUARY 27

Antibodies as Biopharmaceuticals

Janine Schuurman, Genmab B.V., Netherlands
A Therapeutic Antibody Panorama: Highways, Scenic Routes and Dead-Ends

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Principles of Effective Antibody Therapeutics

Marie H. Kosco-Vilbois, NovImmune SA, Switzerland
Bringing Bispecific Molecules to the Clinic

Emma M. Lees, Jounce Therapeutics, USA
JTX-2011: Mechanism of Action of an Agonist Antibody Targeting ICOS

Short Talk(s) Chosen from Abstracts

Antibody Fc-Mediated Mechanisms I

Pamela J. Bjorkman, California Institute of Technology, USA
Engineering Antibodies against HIV-1

Jan Terje Andersen, Oslo University Hospital, Norway
Engineering the Antibody Fc Domain for Improved Function

Marjolein van Egmond, VU University Medical Center, Netherlands
Translating Antibody – Effector Cell Cross-Talk to Immunotherapy

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 28

Antibody Fc-Mediated Mechanisms II

Paul W. H. I. Parren, Leiden University, Netherlands
Complement Activation at the Molecular Level

Suzan Rooijackers, UMC Utrecht, Netherlands
EMBO Young Investigator Lecture: Antibody-Mediated Killing of Bacteria by Complement

Galit Alter, Ragon Institute of MGH, MIT and Harvard, USA
Systems-Level Serology of Antibody Responses to Infectious Disease

Richard S. Blumberg, Brigham and Women's Hospital, USA
Cross-Presentation and Immune Effects Mediated by Antibody

Short Talk(s) Chosen from Abstracts

Workshop 2: Therapeutic Antibodies

Short Talks Chosen from Abstracts

Exploiting Effector Cell Responses

Sergio A. Quezada, University College London, UK
Defining the Role of Fc Receptors and the Tumor Microenvironment in the Activity of Immune Modulatory Antibodies

Laurence Zitvogel, Institut Gustave Roussy, France
The Microbiome and Checkpoint Blockade Therapy

Jeffrey Steven Miller, University of Minnesota, USA
Strategies to use Trispecific Killer Engagers to make Nk Cells Antigen Specific

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 1

Novel Ways to Deliver Antibody Therapy

Ugur Sahin, TRON – Translationale Oncology, Germany
Antibody and mRNA-Based Therapeutics

Mark Cobbold, Massachusetts General Hospital, USA
Retargeting T Cells for Tumor Therapy

Hidde L. Ploegh, Boston Children's Hospital, USA
Single-Domain Intracellular Antibodies

Ronald C. Desrosiers, University of Miami Miller School of Medicine, USA
Adenovirus-Associated Virus-Mediated Delivery of Antibodies

Short Talk(s) Chosen from Abstracts

From Molecules to the Clinic

Ira Mellman, Genentech, Inc., USA
Antibodies in Cancer Immunotherapy

David E. Szymkowski, Xencor, USA
Novel Engineered Antibodies to Treat Inflammatory and Allergic Disease

John M. Lambert, ImmunoGen, Inc., USA
ADC, the Magic Bullet Revisited

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: Translating Molecules into Treatments (C1)

February 25-March 1, 2018 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Paul W. H. I. Parren and Erica Ollmann Saphire

Sponsored by Bioverativ Therapeutics

Abstract & Scholarship Deadline: October 24, 2017 / Abstract Deadline: November 21, 2017 / Discounted Registration Deadline: December 19, 2017

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: Translating Molecules into Treatments (C1)

February 25-March 1, 2018 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Paul W. H. I. Parren and Erica Ollmann Saphire

Sponsored by Bioverativ Therapeutics

Abstract & Scholarship Deadline: October 24, 2017 / Abstract Deadline: November 21, 2017 / Discounted Registration Deadline: December 19, 2017

FRIDAY, MARCH 2

Departure